Hepatitis B immune globulin advisory committee
Executive Summary
FDA's Blood Products Advisory Committee will discuss clinical trials for licensing of hepatitis B immune globulin as treatment to prevent hepatitis B virus and liver disease following liver transplantation in HBV-positive recipients as part of a two-day meeting March 18-19. The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at 8 a.m. both days. [To watch a 1webcast or video of this meeting, go to FDAAdvisoryCommittee.com]...